PLABiologics Secures Seed Funding from CHA Biotech and Seongkwang Medical Foundation

PLABiologics Raises Seed Funding

PLABiologics (플라바이오로직스), a South Korean gene and cell therapy company, has raised a Seed round. The investors are CHA Biotech (차바이오텍) and Seongkwang Medical Foundation (성광의료재단). The specific funding amount was not disclosed.

Company Background

PLABiologics was founded in 2022 as a spinout of CHA University and is based in Seongnam, South Korea. The company operates at the intersection of gene therapy and cell therapy, with a research foundation built on two decades of placenta research conducted at CHA University.

That academic lineage is central to the company's identity. Rather than assembling a pipeline from external licensing, PLABiologics is commercializing a specific body of institutional research into placenta-derived materials and their therapeutic potential.

Therapeutic Focus

PLABiologics develops placenta-derived mesenchymal stem cell therapies. Its lead programs are:

• UNIPla — a placenta-derived mesenchymal stem cell therapy
• SUNIPla — described as non-viral and functionally enhanced

Beyond these lead cell therapies, the company is building pipelines on placenta-derived materials, exosomes and natural-product factors. The stated goal is placenta-based medicines for degenerative and intractable diseases — a category that includes conditions where conventional treatment options remain limited and where cell and gene therapy approaches have attracted sustained research interest.

The distinction between UNIPla and SUNIPla is worth noting. SUNIPla's non-viral and functionally enhanced profile suggests an engineering approach intended to improve on the base platform, which is a common progression for stem cell companies seeking to differentiate within a crowded regenerative medicine field.

Investor Context

The investor list carries strategic weight. CHA Biotech is part of the CHA medical and bioscience group, and CHA University is the institution from which PLABiologics spun out. Seongkwang Medical Foundation adds a second medical foundation investor.

For a Seed-stage cell and gene therapy company, backing from established medical and biotech organizations can matter beyond capital. It can provide access to research infrastructure, clinical networks and translational expertise — resources that are often as important as funding for early-stage therapeutics developers.

The Round

• Round type: Seed
• Investors: CHA Biotech (차바이오텍), Seongkwang Medical Foundation (성광의료재단)
• Amount: Not disclosed
• Lead investor: Not disclosed

What to Watch

PLABiologics is early. Founded in 2022, it is still in the phase where pipeline validation and preclinical progress drive value. The key milestones ahead will be around the UNIPla and SUNIPla programs — specifically, evidence that the placenta-derived approach translates into differentiated therapeutic performance.

The broader placenta-derived materials, exosome and natural-product factor pipelines give the company multiple shots on goal, but also raise the question of focus. For a Seed-stage company, prioritization among these tracks will likely shape how the next round is structured and who participates.

With two medical and biotech-aligned investors on the cap table and a two-decade research base behind the platform, PLABiologics enters its next phase with institutional support and a defined scientific thesis.